公开(公告)号：US10751168B2

公开(公告)日：2020-08-25

申请号：US15567053

申请日：2016-01-20

Applicant: KOWA COMPANY, LTD.

Inventor： Genyo Midorikawa

IPC: A61F2/16 ,  A61M5/31 ,  A61M5/315

Abstract: An intraocular lens insertion apparatus includes an apparatus body configured to include a housing member for housing an intraocular lens and an insertion tube member for ejecting the intraocular lens into an eyeball of a patient, a plunger configured to move in the apparatus body, and a hook member formed on the apparatus body for a user of the intraocular lens insertion apparatus to hook a finger when the user moves the plunger. The plunger is moved to a side of the insertion tube member, the intraocular lens housed in the housing member is pushed by a distal end of the plunger, and the intraocular lens is ejected from the insertion tube member, and a connecting member configured to connect an operability enhancing member for enhancing an operability of the plunger when the plunger is moved with the apparatus body is provided for the apparatus body.

公开(公告)号：US20200246314A1

公开(公告)日：2020-08-06

申请号：US16853121

申请日：2020-04-20

Applicant: KOWA COMPANY, LTD.

Inventor： Yuta Inokuchi ,  Toshiaki Takizawa

IPC: A61K31/423 ,  A61K31/455

Abstract: This invention provides a combination-drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemic conditions such as hyper-LDL cholesterolemia in mammals, including humans. This invention pertains to a drug composition for preventing and/or treating dyslipidemia and the like, the drug composition including the following: (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate of either; and nicotinic acid and nicotinic-acid amide, collectively referred to as niacin, an ester derivative thereof, a salt thereof, or a solvate of any of these.

公开(公告)号：US20200215050A1

公开(公告)日：2020-07-09

申请号：US16647448

申请日：2018-09-13

Applicant: National University Corporation Hamamatsu University School of Medicine ,  Kowa Company, Ltd.

Inventor： Naoki Unno ,  Hiroki Tanaka ,  Tatsuro Yata ,  Keisuke Inoue ,  Yuichi Makinose ,  Noboru Kaneta

IPC: A61K31/4704 ,  A61P9/14

Abstract: The present invention addresses the problem of providing a therapeutic agent for abdominal aortic aneurysms, with which pharmacotherapy is possible.The present invention provides a therapeutic agent for an aortic aneurysm comprising, as an active component, (−)-6-[3-[3-cyclopropyl-3-[(1R,2R)-2-hydroxycyclohexyl]ureido]propoxy]-2(1H)-quinolinone or a salt thereof, or a solvate of these.

公开(公告)号：US10701258B2

公开(公告)日：2020-06-30

申请号：US16474620

申请日：2018-01-30

Applicant: KOWA COMPANY, LTD.

Inventor： Tomohisa Azegami

IPC: H04N5/232 ,  H04Q9/00 ,  H04W84/12 ,  H04L5/00

Abstract: [Problem] To enable imaging to be performed with appropriate timing.[Solution] In a camera manipulation device 1 according to the present invention, a trigger signal T12 is issued and imaging is begun when a prescribed command is transmitted from a control circuit side to an imaging unit side (see S12). Because the issuance of such trigger signal T12 is not accepted before a character reception start command is issued, it is possible to perform imaging with appropriate timing.

公开(公告)号：US20200167915A1

公开(公告)日：2020-05-28

申请号：US16637216

申请日：2018-08-06

Applicant: KOWA COMPANY, LTD.

Inventor： Reiko ARITA ,  Katsumi YABUSAKI

IPC: G06T7/00 ,  A61B3/00 ,  A61B5/00

Abstract: Provided are a method, a computer program and a device for noninvasively evaluating a state of a tear fluid and a tear fluid amount of a tear meniscus.Included are a binarization step of binarizing a tear meniscus image, obtained by capturing at least a part of a tear meniscus of a subject, using a predetermined threshold value; an extraction step of extracting a high luminance region indicating a tear meniscus part from the binarized image; and an evaluation step of evaluating a tear fluid state on the basis of the high luminance region.

公开(公告)号：US20200157712A1

公开(公告)日：2020-05-21

申请号：US16631349

申请日：2018-08-01

Applicant: KOWA COMPANY, LTD.

Inventor： Toshitada SUEOKA

IPC: D03D15/08 ,  D02G3/32 ,  D06C9/00 ,  D02G3/34

Abstract: Provided are: a cloth including thermoplastic synthetic staple fibers, especially a woven or knitted fabric in which occurrence of pilling is suppressed and a reduction of the strength or deterioration of the texture of the cloth is suppressed; and a method for manufacturing the cloth. An anti-pilling cloth including thermoplastic synthetic staple fibers, wherein the anti-pilling cloth is characterized by having, on the surface of at least one side of the cloth, melt balls at ends of the staple fibers and polishing traces of melt balls at fluff tip ends of the staple fibers; and a method for manufacturing the anti-pilling cloth.

公开(公告)号：US20200154995A1

公开(公告)日：2020-05-21

申请号：US16627683

申请日：2018-07-03

Applicant: KOWA COMPANY, LTD.

Inventor： Katsumi YABUSAKI

IPC: A61B3/10 ,  A61B3/14 ,  G06T7/00

Abstract: A method, a computer program and a device for evaluating a tear fluid layer non-invasively. The method, computer program, and device include a step of detecting a time when color information in a predetermined region in a tear fluid layer interference fringe image changes by a threshold value or more as an eyelid opening time, a step of extracting an image at the time when the predetermined time has passed from the eyelid opening time as an extracted image from the tear fluid interference fringe images, a determination value calculation step of calculating a determination value from the color information in a pixel in a local region by scanning a predetermined target region, a step of detecting a corresponding pixel by comparing the calculated determination value and a threshold value, and an evaluation step of evaluating tear fluid layer breakdown by comparing the detected pixel and a threshold value.

公开(公告)号：US20200151909A1

公开(公告)日：2020-05-14

申请号：US16609669

申请日：2018-04-27

Applicant: KOWA COMPANY, LTD.

Inventor： Katsumi YABUSAKI

IPC: G06T7/90

Abstract: Provided are an analysis evaluation method and device, and a computer program for the state of a subject surface in a still image. The method includes: a step of acquiring color information of each pixel in a predetermined region in a still image, a step of calculating a numerical value indicating a diversity of color from the acquired color information, a step of calculating an average value of the color information, and a step of calculating a coefficient of variation on the basis of the calculated numerical value indicating the diversity of color and the calculated average value of the color information. Herein, the coefficient of variation is used as an index for evaluating the surface state of an object.

公开(公告)号：US20200147051A1

公开(公告)日：2020-05-14

申请号：US16726857

申请日：2019-12-25

Applicant: Kowa Company, Ltd.

Inventor： Ryu Oshima ,  Kazuhito Suehira ,  Gary Gordon

IPC: A61K31/423 ,  A61P3/06

Abstract: The present invention relates to pharmacological interventions with pemafibrate for moderate or severe hypertriglyceridemia.

公开(公告)号：US20200022960A1

公开(公告)日：2020-01-23

申请号：US16477416

申请日：2018-01-11

Applicant: Kowa Company, Ltd.

Inventor： Yusuke Sasaki ,  Masato Asahiyama ,  Toshiya Tanaka

IPC: A61K31/423 ,  A61P1/16

Abstract: The present invention addresses the problem of providing a medicinal composition and a drug combination by which nonalcoholic fatty liver disease and nonalcoholic steatohepatitis can be prevented and/or treated. The present invention provides a combination of a peroxisome proliferator-activated receptor (PPAR) α agonist with a sodium glucose cotransporter 2 (SGLT2) inhibitor, which is to be used for preventing and/or treating nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.